Navigation Links
SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
Date:2/25/2013

investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.

Our organization consists of several distinct group companies:

SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
SHL Pharma
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries

For additional information visit http://www.shl-group.com or contact us at info (at) shl-group (dot) com

SHL Media Contact
Steven R. Kaufman
Marketing Director
pr (at) shl-group (dot) com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10458242.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
2. VIC Investor Network to Significantly Accelerate Technology Company Growth
3. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
4. PDL BioPharma to Present at Two Upcoming Investor Conferences
5. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
11. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
(Date:9/22/2014)... , Sept. 22, 2014 US demand to ... for specialty biocides is forecast to rise 3.9 percent ... terms, demand is projected to increase 1.3 percent per ... A strong rebound in construction expenditures will support demand ... coatings markets, while growth in consumer spending and manufacturing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Invisible ... diagnostics for the food and beverage industries, announced ... be distributed under a non-exclusive agreement by Enartis, ... services. , Enartis, an Esseco Group company headquartered ... winemakers in California and other global markets for ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... ST. LOUIS, Oct. 2 /PRNewswire-FirstCall/ -- ... ) has elected Dr. George M. Church as a Director ... Professor of Genetics at the Harvard Medical School and Director ... Dr. Church pioneered technology innovations early in the development of ...
... Host Conference Call-- , CALGARY, Oct. 2 /PRNewswire-FirstCall/ - ... it has reached an agreement with the U.S. Food ... (SPA) process for the design of a Phase 3 ... in patients with platinum-refractory head and neck cancers. The ...
... ... the recipients of the 2009 Orange County Emerging Growth Awards, recognizing companies headquartered in ... significant growth over the last 12 months and that have made a positive impact ... ...
Cached Biology Technology:Sigma-Aldrich Elects George M. Church as Director 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4
(Date:9/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD ), a ... market, issues the following corporate shareholder update following the ... Letter from the CEO : ... joined the NASDAQ to support ramping of production of ... authentication products and services. This strategic achievement positions NXT-ID to ...
(Date:9/21/2014)... (black-eyed peas) is a fascinating example of how science ... the story of the scientist behind the research. ... the 21st Century to serve as an accessible summary ... recently published by the Crop Science Society of America, ... , Singh has devoted his life,s work to solving ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Immune system of newborn babies is stronger than previously thought 2
... release is available in German . ... travel of tomorrow is meant to become quieter, cleaner and ... to accomplish just that as part of the EU ... technical aspects of air travel to the test, evaluating and ...
... study has highlighted the sensitivity of Australia,s species and ... ways of thinking about biodiversity conservation. ,Climate change ... natural landscapes by 2030, lead researcher, CSIRO,s Dr Michael ... be very significant and widespread. Many of the environments ...
... a leading software company in the clinical ... Next Generation Biobanking software platform for biomarker-based ... and academic research centers involved in biomarker-based ... effectively conduct externalized, science-driven collaborative studies. ...
Cached Biology News:Fraunhofer supports continuation of 'Clean Sky' program 2Major changes needed to protect Australia's species and ecosystems 2BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research 2
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
... 4 deuterium atoms at the 9, 10, 12, ... as an internal standard for the quantification of ... produced by incubation of linoleic acid with plant ... inhibit the adhesion of tumor cells to the ...
... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
...
Biology Products: